FGFilip Grydź

Filip Grydź

*This is an algorithmically generated author record based on publicly available information.

Filip Grydź has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • THE IMPACT OF OMEGA-3 FATTY ACIDS SUPPLEMENTATION ON REDUCING EXERCISE-INDUCED MUSCLE DAMAGE: A REVIEW

    by Aneta Rasińska, Justyna Jachimczak, Piotr Rzyczniok, Paulina Bala, Justyna Matusik, Aneta Rostkowska, Filip Grydź, Joanna Filipow, Sebastian Kupisiak, Natalia Pasierb, et al.

    Ackground: Delayed-onset muscle soreness (DOMS) is a common consequence of eccentric exercise, often impairing recovery and performance. Omega-3 polyunsaturated fatty acids (PUFAs), particularly EPA and DHA, have been proposed as potential nutritional interventions to mitigate DOMS through anti-inflammatory and membrane-stabilizing mechanisms. Methods: A structured literature search of PubMed, Scopus, and Web of Science (2000–2024) identified 14 randomized controlled trials and clinical studies investigating the effects of omega-3 supplementation on DOMS and exercise-induced muscle damage (EIMD). Results: Most studies used daily doses of 1.8–3 g of combined EPA/DHA for at least 3–4 weeks. Findings suggest that omega-3 supplementation may reduce perceived muscle soreness 24–72 hours post-exercise and exert mild anti-inflammatory effects. However, heterogeneity in study design, dosage, duration, and outcome measures limits the comparability and generalizability of results. Conclusion: Omega-3 fatty acids may offer a modest adjunctive benefit in reducing DOMS and supporting recovery. Further well-controlled trials are needed to clarify dose–response relationships and population-specific effects.


  • ADVANCES IN THE MANAGEMENT OF GASTRIC LYMPHOMAS: INTEGRATING GLOBAL EVIDENCE INTO CLINICAL PRACTICE

    by Justyna Jachimczak, Aneta Rasińska, Piotr Rzyczniok, Paulina Bala, Justyna Matusik, Aneta Rostkowska, Filip Grydź, Joanna Filipow, Sebastian Kupisiak, Natalia Pasierb, et al.

    Introduction and purpose: This narrative review explores gastric lymphomas, focusing on their epidemiology, diagnosis, treatment, and prognosis. It aims to integrate international guidelines with Polish clinical practice to address the diagnostic and therapeutic challenges associated with these rare and histologically diverse malignancies. Results: Primary gastric lymphomas, particularly MALT lymphoma and DLBCL, require individualized management. MALT lymphoma is highly responsive to Helicobacter pylori eradication, with success rates reaching up to 80% in localized cases. However, the presence of the t(11;18)(q21;q21) translocation indicates a reduced response and necessitates additional treatment, such as radiotherapy or immunochemotherapy. For gastric DLBCL, R-CHOP remains the standard of care, and surgery has been largely replaced by organ-preserving strategies. Polish clinical protocols align with international standards, emphasizing bismuth-based eradication regimens and the growing role of molecular diagnostics. Conclusion: Effective management of gastric lymphomas requires a multidisciplinary and individualized approach that accounts for histologic subtype, stage, H. pylori status, and molecular features. Non-surgical, evidence-based strategies significantly improve outcomes, with Polish practice reflecting global standards in antibiotic stewardship and precision oncology.

  • Open Access

    High-Frequency Ultrasonography As An Innovative Diagnostic Method in Dermatology

    by Aneta Rasińska, Piotr Rzyczniok, Anna Rzyczniok, Weronika Rasińska, Justyna Jachimczak, Filip Grydź, Joanna Filipow, Anna Rebizak, Paulina Bala, Aneta Rostkowska, et al.

    Ultrasonography is now a standard, non-invasive imaging technique used in many areas of medical diagnostics. Currently it is also an important tool in the diagnosis of skin diseases. In clinical practice, High Frequency Ultrasonography (HFU) is used more and more often because it has proved to be a valuable diagnostic tool for assessing the condition of skin tissue. The physical conditions of HFU make it possible to estimate the parameters of the skin structure, such as thickness and echogenicity (a feature related to the center) of its layers in relation to the surrounding tissues. Therefore, HFU allows to obtain information concerning the condition of the examined area of the skin., the rate of lession development and the effectiveness of implemented theraphy. HFU is applied in the imaging of focal skin lesions, including melanoma, basal-cell carcinoma, inflammatory skin diseases, diseases associated with its thickening and in aesthetic medicine and cosmetology. The aim of this chapter is to familiarize the reader interested in dermatology and in particular diagnostics in this field, the possibilities associated with the use of HFU. Material and Methods – Narrative literature review combined with technical exposition of HFU devices (20–100 MHz mechanical and broadband linear probes). The authors summarise depth–resolution trade-offs, standard scanning protocols and representative clinical images to illustrate HFU performance across anatomical sites and skin conditions. Findings – HFU resolves skin strata down to 10 μm, quantifies tumour thickness (Breslow depth) pre-operatively, delineates BCC margins, detects subepidermal low-echogenic band as a marker of photoageing or atopic dermatitis severity, and guides real-time assessment of fillers, vascular flow, oedema and fibrosis. Frequencies of 20–30 MHz visualise full dermis, 50 MHz epidermis/upper dermis, while lower (7–12 MHz) probes image deeper lesions and lymph nodes.

  • Open Access

    Immunotherapy as an Innovative Treatment for Non-Small Cell Lung Cancer – A Comprehensive Literature Review

    by Aneta Rasińska, Piotr Rzyczniok, Anna Rzyczniok, Weronika Rasińska, Justyna Jachimczak, Filip Grydź, Joanna Filipow, Anna Rebizak, Paulina Bala, Aneta Rostkowska, et al.

    Lung cancer has, for several decades, been the second most frequently diagnosed malignancy and the leading cause of cancer death worldwide. It continues to pose a significant burden on healthcare systems and a serious challenge for clinicians and patients. The majority of patients present with advanced disease at diagnosis, and most survive less than five years. Although novel targeted therapies have been introduced in recent years, there remains a significant demand for treatments capable of improving response and prolonging survival while having minimal impact on quality of life. Recent clinical evidence supporting immunotherapeutic approaches indicates that they may represent the next major therapeutic breakthrough in lung cancer management. Non-small cell lung cancer (NSCLC), which accounts for about 85% of lung cancers, was once considered a non-immunogenic disease; yet, as with several other malignancies, emerging data suggest that in most cases, the lack of immune response is functional and can be therapeutically overcome. Purpose: To provide a comprehensive review of immunotherapy as an innovative therapeutic approach for non-small cell lung cancer (NSCLC), highlighting the role of key immune mechanisms and checkpoint inhibitors. Material and Methods: The authors conducted a detailed literature review examining the immune context of NSCLC, discussing the significance of PD-1/PD-L1 and CTLA-4 checkpoints, relevant clinical trials, and emerging biomarkers like PD-L1 expression and tumor mutational burden. Findings: Immunotherapy, particularly PD-1/PD-L1 inhibitors, substantially improves survival in advanced NSCLC and can be enhanced by combination strategies. Biomarkers help identify patients most likely to benefit while guiding treatment choices.